Skip to Content

Avax Technologies Inc AVXT

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

AVXT is trading at a 66% discount.
Price
$0.00
Fair Value
$9.89
Uncertainty
Extreme
1-Star Price
$2.27
5-Star Price
Economic Moat
Mjs
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if AVXT is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.00 / $0.00
Market Cap
$14,260.58
Volume/Avg
29,410 / 28,205

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Avax Technologies Inc is a development stage biotechnology company. The company is engaged in the development and commercialization of individualized vaccine therapies and other technologies for the treatment of cancer. It is also involved in the development and commercial readiness in the immuno-oncology arena.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
29
Website

Valuation

Metric
AVXT
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
No chart available

Financial Strength

Metric
AVXT
Quick Ratio
0.11
Current Ratio
0.16
Interest Coverage
Quick Ratio
No chart available

Profitability

Metric
AVXT
Return on Assets (Normalized)
−144.65%
Return on Equity (Normalized)
−482.11%
Return on Invested Capital (Normalized)
−482.00%
Return on Assets
No chart available
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRJcjgztnjnBkdj$557.8 Bil
VRTX
Vertex Pharmaceuticals IncRhtymdhbXhvmflh$104.7 Bil
REGN
Regeneron Pharmaceuticals IncXkrbbvymvTtlqyj$99.6 Bil
MRNA
Moderna IncKsvktlgwWgdd$38.8 Bil
ARGX
argenx SE ADRHnzvzrqhHyjz$21.4 Bil
BNTX
BioNTech SE ADRPdrdkktTmnsq$21.3 Bil
ALNY
Alnylam Pharmaceuticals IncNnvnxmbgdRwkgks$18.4 Bil
BMRN
Biomarin Pharmaceutical IncPvqrvdwrnJfvrk$17.5 Bil
RPRX
Royalty Pharma PLC Class AQmgkqjnwsZlwxlr$12.4 Bil
INCY
Incyte CorpDqgkyxnCprfyv$11.9 Bil

Sponsor Center